455 A phase II study of first-line combination chemotherapy with docetaxel and gemcitabine in anthracycline-pretreated, Her-2 negative metastatic breast cancer (MBC)

Lenz, F.; Beldermann, F.; Geberth, M.; Bastert, G.; Schneeweiß, Andreas

doi:10.1016/s1359-6349(03)90487-3

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because gemcitabine and docetaxel are highly active in breast cancer but have different toxicity profiles and an absence of antagonism in in vitro studies, different doses and schedules of the gemcitabine-docetaxel combination have been tested in phase II trials in metastatic breast cancer [21][22][23][24][25][26][27][28][29][30][31], with response rates in first-line disease ranging from 54% to 76.7%. One trial of gemcitabine 2500 mg/m 2 and docetaxel 65 mg/m 2 delivered every 2 weeks in 48 evaluable patients with advanced breast cancer reported an ORR of 75% [29].…”

Section: Introductionmentioning

confidence: 99%

Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study

et al. 2007

View full text Add to dashboard Cite

show abstract

“…The published phase II data on taxane–gemcitabine combinations describe impressive response rates of between 33% and 79% 8,10–21 in metastatic breast cancer. These studies display great heterogeneity.…”

Section: Introductionmentioning

confidence: 99%

Phase II study of gemcitabine and docetaxel in combination for the treatment of metastatic breast cancer

Goel

Abdi

Lewis

et al. 2009

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Aim: Gemcitabine (G) and docetaxel (D) have both shown activity in the treatment of anthracyclinepretreated patients with metastatic breast cancer. This phase II study was designed to evaluate the safety and efficacy of the GD combination. Methods: Patients with measurable locally advanced or metastatic breast cancer who had previously received anthracycline-based therapy were eligible. The patients received D 40 mg/m 2 followed by G 800 mg/m 2 IV on days 1 and 8 every 3 weeks for a maximum of eight cycles. Results: Thirty patients were enrolled and received a median of five cycles (range 0-8). Of these, 24 were evaluable for efficacy, with an overall response rate of 29.2% (95% CI, 12.6-51.1%). An additional 36.7% had a stable disease for an overall clinical benefit of 65.9%. The median duration of response was 2.1 months (95% CI, 2.0-3.6 months) and the median time to disease progression was 5.5 months (95% CI, 2.0-8.9 months). The median survival time was 16.7 months (95% CI, 7.3-32.0 months). Myelosuppression was the major toxicity, with grade 3/4 neutropenia in 73.3% of patients and febrile neutropenia in 6.7%. Conclusion: Weekly G and D is an active and safe regimen in treating metastatic breast cancer. The response rate was lower than that previously reported for this combination, which may relate to the lower doses used and the weekly D schedule. It may be worthwhile to further explore this combination to determine the optimal dosing schedule.

show abstract

“…Both Fountzilas et al 16 and Lenz et al 17 used lower doses of gemcitabine at 1000 mg/m 2 on days 1 and 8, with docetaxel, 75 mg/m 2 , on day 1. In the first trial, although all patients were notably anthracycline resistant, median survival surpassed 1 year.…”

Section: Introductionmentioning

confidence: 99%

“…Collectively, these and other studies demonstrate that the gemcitabine-docetaxel doublet may serve as a potent regimen and, irrespective of the schedule used, response rates range from 36% to 79% [16][17][18][19][20][21][22] .…”

Section: Introductionmentioning

confidence: 99%

Docetaxel and Gemcitabine in the Treatment of Metastatic Breast Carcinoma: A Dose Finding Study

Leonardi¹,

Palmisano²,

Pepe³

et al. 2009

Tumori

View full text Add to dashboard Cite

show abstract

455 A phase II study of first-line combination chemotherapy with docetaxel and gemcitabine in anthracycline-pretreated, Her-2 negative metastatic breast cancer (MBC)

Cited by 6 publications

References 0 publications

Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study

Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study

Phase II study of gemcitabine and docetaxel in combination for the treatment of metastatic breast cancer

Docetaxel and Gemcitabine in the Treatment of Metastatic Breast Carcinoma: A Dose Finding Study

Contact Info

Product

Resources

About